Targeting GRP94 with a specific monoclonal antibody or peptide-based inhibitor p37 disrupted HER2 dimerization and led to HER2 degradation, which subsequently decreased tumor cell growth and increased apoptosis (57, 78). This evidence concerns the gene ERBB2 and neoplasm.